Review       Open Access

# The Study Progress of B Cells and Neuroimmunological Diseases

**Md Rezaul Karim and Yun-fu Wang**[*]

*Department of Neurology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P. R. China*

**\*Corresponding author:** Yun-fu Wang, Department of Neurology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P. R. China, E-mail: wyfymc@163.com

## Abstract

B cells have both positive and negative regulatory roles during immune responses; they have role in the pathogenesis of various neuroimmunological diseases such as Myasthenia gravis (MG), Multiple sclerosis (MS), Guillain-Barre syndrome (GBS), and Lambert-Eaton myasthenic syndrome (LEMS). B cells can positively regulate immune responses by producing antigen-specific antibody, inducing optimal T cell activation and cytokine production. The pathogenic role of B cells and autoantibodies in neuroimmunological diseases, as reviewed here, provides information towards the research progress in the progressive role of B cells in neuroimmunological diseases. It is expected that the ongoing research on B cells and neuroimmunological diseases will contribute to the clinical applications, and better understanding of the etiology of neuroimmunogical diseases.

## Introduction

B cells are now well established to have both positive and negative regulatory roles during immune responses [1]. B cells can positively regulate immune responses by producing antigen-specific antibody and inducing optimal T cell activation [2,3]. B cells can also negatively regulate cellular immune responses through their production of immune modulatory cytokines. B cell-negative regulation of immune responses has been demonstrated in a variety of mouse models of autoimmunity and inflammation [1,4-13]. The important negative regulatory roles of B cells in immune responses are now broadly recognized [1,14,15]. The regulatory role of B cells in autoimmune diseases was first reported by Janeway and colleagues in EAE. The existence of regulatory B cells were subsequently confirmed by other investigators [4,16-18]. These studies indicate that, like their T cell counterparts, B cells can be divided into functionally distinct regulatory subsets capable of inducing immune tolerance [1,15,18-21]. Autoimmune disorders affect 5-10% of the general population [22], and often involve central nervous system (CNS) and peripheral nervous system (PNS). In the context of autoimmune neurological disorders, B cells have traditionally been associated with the production of auto-antibodies from plasma cells, the end products of B cell differentiation [23-25]. In most autoimmune neurological disorders, the auto-antibodies are directed against cytosolic antigens and might not be directly involved in tissue injury. In such cases, B cells might still participate in the autoimmune process through antibody-independent mechanisms that include antigen presentation, co-stimulation, cytokine production, and coordination of T cell functions [25,26].

## B cells Overview

B cells or B lymphocytes are the critical component of adaptive immune response. B cells are functioned to produce antibody to a specific antigen in response of pathogen such as bacteria, viruses; release interleukin (IL) producing cytokines (Figure 1). B cells can be involved in cell mediated immune responses. B cells express clonally distributed antigen presenting receptors (BCRs) that binds to one particular antigen. Naive B cells (not exposed to antigen) are able to recognize their cognate antigen. Since there are millions of B cells in the body, and naive B cells only live a few days, and more than 90% of these cells die before they have come into contact with an antigen. Once the B cell reaches maturity, it has a B cell receptoron its surface. The B cell receptor (BCR) is a protein that distinguishes the B cell from other lymphocytes. The mature B cell expresses both the Immunoglobulin M (IgM) and the Immunoglobulin M (IgD) [27-29]. The B cell receptor is critical for B cell function, toward production of antibodies, as well as for their functioning as antigen-presenting cells (APCs).



Figure 1: B cells overview.

The mature B cells circulate in the bloodstream and lymph nodes, searching for foreign substances like bacteria, viruses that may harm the body. These B cells are also called naive cells because they have not encountered an antigen yet [30,31]. A mature B cell can differentiate

into several types of B cells, most common being plasma and memory B cells [32,33].

## Regulatory B cells

Regulatory B cells (Bregs) are those immunosuppressive cells, which support immunological tolerance. Over the last decade, the role of Bregs in suppressing pathological immune responses has been widely recognized. In these recent years multiple studies in both mice and humans have demonstrated that Bregs suppress inflammatory responses primarily via the provision of IL-10 [14]. These cells regulate the immune system by various mechanisms. The main mechanism is through the production of IL-10, IL-35, and transforming growth factor (TGF-β) [34]. The regulatory effects of Bregs were described in various models of inflammation, autoimmune diseases, transplantation reactions, and in anti-tumor immunity. Bregs can develop from different subsets of B cells [35]. B cells generally are considered to act as positive regulators of immune responses by promoting antigen presentation for optimal T cell activation and by producing antibodies, but now it is clear that Bregs are essential for inducing immune tolerance by negatively regulating immune responses via IL-10 production [12].

## B cells and Neuroimmunological diseases

In several neurological diseases, including Myasthenia gravis and certain neuropathies, the autoantibodies are pathogenetic, exerting a direct effect on self-antigens either by functioning as neutralizing antibodies or by activating and fixing complement on the targeted tissues [25,26,36]. B cell functions in neuroimmunological diseases through production of antibodies that cause tissue damage; acting as APCs that cause cytokine production; production of proinflammatory cytokines that cause activation of macrophages and enhance tissue damage; neolymphogenesis [37]. Therefore, further research on neuroimmunogical diseases such as Myasthenia gravis, Multiple sclerosis, Guillain-Barre syndrome, and Lambert-Eaton myasthenic syndrome may be an advantage in new therapeutic role in future.

## B cells and Myasthenia Gravis

Myasthenia gravis is an autoimmune disease that affects the transmission of signals from nerves to muscles. It is caused by a defect in the transmission of nerve impulses to muscles. It occurs when normal communication between the nerve and muscle is interrupted at the neuromuscular junction - the place where nerve cells connect with the muscles they control. Approximately 15-20% of people with Myasthenia gravis develop severe, potentially life-threatening respiratory impairment, often within the first year of illness which is a medical emergency called Myasthenia crisis and necessitates mechanical ventilation. The onset of the disorder can be sudden. The diagnosis of MG may be delayed if the symptoms are subtle or variable [37]. MG can be difficult to diagnose, as the symptoms can be subtle and hard to distinguish from both normal variants and other neurological disorders [38]. Approximately 85% of patients with generalized myasthenia gravis have circulating anti-AChR antibodies [39]. Autoantibodies to muscle-specific tyrosine kinase (MuSK) [38-40] are found in 38-47% of patients with MG who do not have detectable antibodies to the acetylcholine receptor (AChR) [40-42]. Anti-AChR or MuSK autoantibodies are produced by B cells with the help of T cells and other lymphocytes [43]. It has been reported that B cell depletion with rituximab treatment has long-lasting effects on MuSK MG [44]. The outcome in cohort was consistent with the

finding. Interestingly, MuSK MG patients also had a tendency for faster B10 cell repopulation during the course of rituximab therapy. It has been found that, a subset of regulatory B (B10) cells is highly relevant to the pathogenesis of MG [43]. The concept of regulatory B cells has been strongly associated with IL-10 productions. The regulatory function of B cells has been associated with the presence and activation of molecules such as CD19, CD1d. Alterations in signaling by any of these pathways leads to a marked defect in Bregs and to increased clinical symptoms and pro-inflammatory signs in autoimmune diseases in humans [45]. To determine whether breakdown in immune tolerance in Myasthenia gravis may be attributable to a reduction in B10 cells. Through an observation may be noticed a whether reduction of B cells capable of producing IL-10 in patients with MG. A compare studies can be made between healthy controls and patients with Myasthenia gravis by which expression of B10 cells such as IL-10 expression, and B cells subsets such as CD19, CD5, CD1d expression can be studied. The reduction of expression in MG could be secondary to the pathogenesis of MG and the outcome of these studies may lead to an effective treatment progress of Myasthenia gravis patients.

## B cells and multiple sclerosis

Multiple sclerosis is an inflammatory demyelinating disease affecting the CNS. In MS, the immune system attacks the myelin sheath that covers nerve fibers and causes communication problems between the brain and rest of the body. Eventually, MS can cause the nerves themselves to deteriorate or become permanently damaged. B cells are thought to play a pathogenic role in MS, and this idea is supported by the reduction of disease in MS patients undergoing antibody mediated B cell depletion therapy. In contrast, in EAE, a mouse model of MS, B cells have been shown to play a regulatory role. This is suggestive of a dual role for B cells in CNS autoimmunity. It is possible that a critical balance between the pathogenic and regulatory populations of B cells might be involved in the manifestation of the disease [46]. While the majority of B cells stimulate the immune system and contribute to antigen clearance and inflammation, some B cells suppress immune functions. These Bregs are a small subset of B cells with CD19, CD5, CD1d surface markers in mice [13], and it has been shown that treatment with autologous Bregs in mice ameliorates EAE [47]. A study found that the levels of IL-10 are lower in untreated MS patients compared to patients receiving anti-inflammatory drugs [48,49]. In a recent study, the phenotype and frequency of B cell subsets in peripheral blood from 32 MS patients and 34 healthy controls were examined using flow cytometry and findings were suggestive to altered blood B cell homeostasis in MS patients [50]. In addition, the researchers found that when B cells were reduced to below a threshold of 64 cells per micro liter, disease activity, as measured by appearance of new brain lesions, was significantly reduced [51]. These awaiting findings and ongoing research on immune regulatory function of B cells and MS, could contribute to reasoning about MS pathogenesis; various B cell related mechanisms including investigation of B cell effectors and regulatory functions; understanding of the mechanisms of formation and persistence of tertiary lymphoid tissues in Multiple sclerosis patients.

## B cells and Guillain-Barre syndrome

GBS is a neurological disorder in which the body's immune system attacks part of the PNS. Symptoms of GBS vary from person to person and may be mild or severe. Most often, the first prominent symptom is weakness felt in both legs. The weakness is accompanied by paresthesia

[52]. Up to two thirds of cases may have an antecedent flu-like illness or gastroenteritis triggering the immune response. Elevated titers of anti-nerve antibodies are frequently found but their presence usually has limited clinical significance. Clinically, GBS manifests as an acute peripheral neuropathy with symmetric weakness reaching a peak by 4 weeks from onset, hyporeflexia or areflexia and cytoalbuminemic dissociation in the cerebrospinal fluid (CSF) with an elevated protein content and normal cell count. Diagnosis can usually be made on clinical grounds, but lumbar puncture and electrophysiological studies can help to substantiate the diagnosis and to differentiate demyelinating from axonal subtypes of GBS [53] (Table 1).

| Subtypes | Antibodies |
| --- | --- |
| Acute inflammatory demyelinating polyneuropathy (AIDP) | various antibodies |
| Acute motor axonal neuropathy (AMAN) | GM1a, GM1b, GD1a, GalNAc-GD1a |
| Acute motor sensory axonal neuropathy (AMSAN) | GM1, GD1a |
| Pharyngeal-cervical brachial variant | GT1a, GQ1b, GD1a |
| Miller fisher syndrome (MFS) | GQ1b, GT1a |

**Table 1:** The subtypes of GBS and relevant antibodies are recognized [54-57].

In a recent study, 59 GBS cases were compared to 58 neurological controls and 60 non-neurological controls to investigate the association of anti-ganglioside antibodies in GBS and other neurological disorders. Anti-gangliosid1e IgG was present in 82% and IgM in 46% in AIDP patients, 70% and 44% respectively in AMAN subgroup and 38% each in AMSAN subgroup [58]. In GBS, it is possible that the virus has changed the nature of cells in the nervous system so that, the immune system treats them as foreign cells. Through the investigation of lymphocyte subsets in patients with GBS in comparison with healthy controls and other autoimmune diseases may lead to the key role of activation of immune system inappropriately. A compared study of the peripheral blood B lymphocyte subsets such as CD19 expression and counting by flow cytometric analysis may show the characteristic features of cell subsets in relation with the pathogenesis of Guillain-Barre syndrome.

## B cells and Lambert-Eaton Myasthenic syndrome

In the LEMS, antibodies against voltage-gated calcium channels (VGCC), decrease the amount of calcium that can enter the nerve ending, hence less acetylcholine (ACh) can be released from the neuromuscular junction. Apart from the skeletal muscle, the autonomic nervous system also requires ACh neurotransmission; this explains the occurrence of autonomic symptoms in LEMS [59,60]. To assess the treatment effects of rituximab in patients with Lambert-Eaton myasthenic syndrome, two patients with LEMS were treated with rituximab. The LEMS antibody patients improved following rituximab treatment. As a selective, B cell targeted therapy; rituximab should be considered as a treatment option for patients with LEMS if standard immunosuppressive treatments have been unsuccessful [61]. Further studies may contribute to the treatment progress of patients with Lambert-Eaton myasthenic syndrome.

## Conclusion and Expectation

B cells play significant regulatory roles during immune responses. B cells have both their positive and negative regulatory roles in neuroimmunological diseases including Myasthenia gravis, Multiple sclerosis, Guillain-Barre syndrome, and Lambert-Eaton myasthenic syndrome, etc. B cells function through production of antibodies, acting as APCs, proinflammatory cytokines production. Studies of B10 expressions from MG patients and healthy controls expected to be effective on MG treatment progress in future. Through further studies of B cells and MS in comparison with healthy controls may contribute to reasoning about MS pathogenesis. Studies of GBS, LEMS, and other neuroimmunological diseases with B cells are growing significantly which can lead to new treatment options. As of expectation, in near future, the current studies on B cells will contribute to the new therapeutic options for these neuroimmunological diseases.

## References

1. Kalampokis I, Yoshizaki A, Tedder TF (2013) IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther 15: S1.
2. LeBien TW, Tedder TF (2008) B lymphocytes: how they develop and function. Blood 112: 1570-1580.
3. DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, et al. (2008) Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 180: 361-371.
4. Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr (1996) Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 184: 2271-2278.
5. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3: 944-950.
6. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF (2008) Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 118: 3420-3430.
7. Fillatreau S, Gray D, Anderton SM (2008) Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 8: 391-397.
8. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK (2002) Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16: 219-230.
9. Mizoguchi A, Bhan AK (2006) A case for regulatory B cells. J Immunol 176: 705-710.
10. Mauri C, Ehrenstein MR (2008) The 'short' history of regulatory B cells. Trends Immunol 29: 34-40.
11. Lund FE (2008) Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 20: 332-338.
12. Bouaziz JD, Yanaba K, Tedder TF (2008) Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 224: 201-214.

13. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, et al. (2008) A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28: 639-650.

14. Mauri C, Bosma A (2012) Immune regulatory function of B cells. Annu Rev Immunol 30: 221-241.

15. DiLillo DJ, Matsushita T, Tedder TF (2010) B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 1183: 38-57.

16. Matsushita T (2010) Regulatory B cell and autoimmune disease. Nihon Rinsho Meneki Gakkai Kaishi 33: 234-241.

17. Lemoine S, Morva A, Youinou P, Jamin C (2009) Regulatory B cells in autoimmune diseases: how do they work? Ann N Y Acad Sci 1173: 260-267.

18. Sheng JR, Quan S, Soliven B (2014) CD1d(hi)CD5+ B cells expanded by GM-CSF in vivo suppress experimental autoimmune myasthenia gravis. J Immunol 193: 2669-2677.

19. Lehmann-Horn K, Kronsbein HC, Weber MS (2013) Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther Adv Neurol Disord 6: 161-173.

20. Giannoukakis N, Trucco M (2012) A role for tolerogenic dendritic cell-induced B-regulatory cells in type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 19: 279-287.

21. Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, et al. (2007) Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 178: 7868-7878.

22. Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 34: J168-177.

23. Shlomchik MJ, Craft JE, Mamula MJ (2001) From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 1: 147-153.

24. Dalakas MC (2008) Invited article: inhibition of B cell functions: implications for neurology. Neurology 70: 2252-2260.

25. Browning JL (2006) B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5: 564-576.

26. Martin F, Chan AC (2006) B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 24: 467-496.

27. Airoldi I, Raffaghello L, Cocco C, Guglielmino R, Roncella S, et al. (2004) Heterogeneous expression of interleukin-18 and its receptor in B-cell lymphoproliferative disorders deriving from naive, germinal center, and memory B lymphocytes. Clin Cancer Res 10: 144-154.

28. Lang ML (2009) How do natural killer T cells help B cells? Expert Rev Vaccines 8: 1109-1121.

29. Benson MJ, Erickson LD, Gleeson MW, Noelle RJ (2007) Affinity of antigen encounter and other early B-cell signals determine B-cell fate. Curr Opin Immunol 19: 275-280.

30. Kaneko Y, Hirose S, Abe M, Yagita H, Okumura K, et al. (1996) CD40-mediated stimulation of B1 and B2 cells: implication in autoantibody production in murine lupus. Eur J Immunol 26: 3061-3065.

31. Ramírez J, Lukin K, Hagman J (2010) From hematopoietic progenitors to B cells: mechanisms of lineage restriction and commitment. Curr Opin Immunol 22: 177-184.

32. Watkins NA, Gusnanto A, de Bono B, De S, Miranda-Saavedra D, et al. (2009) A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood 113: e1-9.

33. Novershtern N, Subramanian A, Lawton LN, Mak RH, Haining WN, et al. (2011) Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 144: 296-309.

34. Rosser EC, Mauri C (2015) Regulatory B cells: origin, phenotype, and function. Immunity 42: 607-612.

35. Vitale G, Mion F, Pucillo C (2010) Regulatory B cells: evidence, developmental origin and population diversity. Mol Immunol 48: 1-8.

36. Dalakas MC (2008) B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 4: 557-567.

37. Angelini C (2011) Diagnosis and management of autoimmune myasthenia gravis. Clin Drug Investig 31: 1-14.

38. Scherer K, Bedlack RS, Simel DL (2005) Does this patient have myasthenia gravis? JAMA 293: 1906-1914.

39. Ragheb S, Lisak RP (2011) B-cell-activating factor and autoimmune myasthenia gravis. Autoimmune Dis 2011: 939520.

40. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, et al. (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7: 365-368.

41. Guptill JT, Yi JS, Sanders DB, Guidon AC, Juel VC, et al. (2015) Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurol Neuroimmunol Neuroinflamm 2: e77.

42. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, et al. (2003) Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126: 2304-2311.

43. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A (2003) Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60: 1978-1980.

44. Sun F, Ladha SS, Yang L, Liu Q, Shi SX, et al. (2014) Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis. Muscle Nerve 49: 487-494.

45. Díaz-Manera J, Martínez-Hernández E, Querol L, Klooster R, Rojas-García R, et al. (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78: 189-193.

46. Rincón-Arévalo H, Sanchez-Parra CC, Castaño D, Yassin L, et al. (2016) Regulatory B Cells and Mechanisms. Int Rev Immunol 35: 156-176.

47. Ray A, Basu S (2014) Regulatory B cells in experimental autoimmune encephalomyelitis (EAE). Methods Mol Biol 1190: 243-255.

48. Rafei M, Hsieh J, Zehntner S, Li M, Forner K, et al. (2009) A granulocyte macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat Med 15: 1038-1045.

49. (2014) American Academy of Neurology (AAN). Targeting B cells may help with multiple sclerosis, study shows Science Daily.

50. Ozenci V, Kouwenhoven M, Huang YM, Xiao B, Kivisakk P, et al. (1999) Multiple sclerosis: Levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment. Scand Immunol 49: 554-561.

51. Habib J, Deng J, Lava N, Tyor W, Galipeau J (2015) Blood B Cell and Regulatory Subset Content in Multiple Sclerosis Patients. J Mult Scler (Foster City) 2: 139.

52. Krumbholz M, Derfuss T, Hohlfeld R, Meinl E (2012) B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 8: 613-623.

53. Burns TM (2008) Guillain-Barré syndrome. Semin Neurol 28: 152-167.

54. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, et al. (2014) Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 10: 469-482.

55. Kusunoki S, Kaida K, Ueda M (2008) Antibodies against gangliosides and ganglioside complexes in Guillain-Barré syndrome: new aspects of research. Biochim Biophys Acta 1780: 441-444.

56. Yuki N, Hartung HP (2012) Guillain-Barré syndrome. N Engl J Med 366: 2294-2304.

57. Willison HJ, Yuki N (2002) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125: 2591-2625.

58. Vaishnavi C, Behura C, Prabhakar S, Sharma A, Kharbanda P (2013) Anti-ganglioside antibodies in patients with Guillain Barré syndrome and other neurological disorders. Indian J Med Microbiol 31: 177-179.

59. Mareska M, Gutmann L (2004) Lambert-Eaton myasthenic syndrome. Semin Neurol 24: 149-153.

60. Verschuuren JJ, Wirtz PW, Titulaer MJ, Willems LN, van Gerven J (2006) Available treatment options for the management of Lambert-Eaton myasthenic syndrome. Expert Opin Pharmacother 7: 1323-1336.

61. Maddison P, McConville J, Farrugia ME, Davies N, Rose M, et al. (2011) The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 82: 671-673.